Arcus Biosciences, Inc. (RCUS)
NYSE • Healthcare
Last close at October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 27
in 23 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arcus Biosciences’ fiscal second quarter of 2026, reported Aug. 5, saw EPS of -$0.72 top the -$0.89 estimate by 19.2%, even as revenue of about $41.0 million fell 74.4% year over year and still came in ahead of the $22.0 million consensus by 86.5%. Gross profit matched revenue at about $41.0 million, which left gross margin near 100%, while operating income was roughly -$96.0 million and operating margin about -234%, reflecting the continued gap between revenue and operating expenses. Net loss came to about $91.0 million, wider than the roughly $8.0 million loss a year ago, and operating cash flow was negative about $119.0 million. EPS improved from -$0.08 a year ago on the same reported basis, but the quarter remained loss-making despite the revenue beat.
Next report — what to expect
Arcus Biosciences, Inc. (RCUS) is scheduled to report on October 27, 2026. Consensus expectations call for EPS of -$0.93 on revenue of $11.0 million. For trailing context, revenue declined -74.4% year over year last quarter. RCUS has beaten EPS in 6 of 8 most recent quarters.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage biopharmaceutical company in biotechnology that discovers and aims to commercialize cancer therapies. In FY2025, the company recorded $247.0 million in revenue. Its drug portfolio centers on immuno-oncology and targeted treatment candidates for solid tumors and genetically defined disease.
Today's Snapshot
The day ended with RCUS 3.1% lower at 24.44, while its sector was flat. Volume was about two-thirds of its usual level.
Trading Volume
Below 10d avg (1.4M)
958.5K
vs S&P 500 Today
Strong Underperformance
-3.91%
Updated: October 2, 2026 at 20:21 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$24.73 - $27.03Sell
- RSI (14)37.19Neutral
- Stochastic %K (14, 3, 3)40.45Neutral
- MACD Level (12, 26)-0.88Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.